MGNX Logo

MacroGenics, Inc. (MGNX) 

NASDAQ$2.22
Market Cap
$139.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
707 of 924
Rank in Industry
403 of 527

MGNX Insider Trading Activity

MGNX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$800,2312100

Related Transactions

Smith Beth AnnVP, Controller & Treasurer0$01$1,083$-1,083
Peters Jeffrey StuartSenior VP and General Counsel0$01$799,148$-799,148

About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug …

Insider Activity of MacroGenics, Inc.

Over the last 12 months, insiders at MacroGenics, Inc. have bought $0 and sold $800,231 worth of MacroGenics, Inc. stock.

On average, over the past 5 years, insiders at MacroGenics, Inc. have bought $12.92M and sold $1.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $669,585 was made by BIOTECH TARGET N V (10 percent owner) on 2023‑10‑02.

List of Insider Buy and Sell Transactions, MacroGenics, Inc.

2025-02-15SaleSmith Beth AnnVP, Controller & Treasurer
423
0.0007%
$2.56$1,083+0.54%
2024-04-04SalePeters Jeffrey StuartSenior VP and General Counsel
51,395
0.0725%
$15.55$799,148-79.89%
2024-03-06SalePeters Jeffrey StuartSenior VP and General Counsel
19,625
0.0317%
$21.50$421,938-82.98%
2024-03-04SaleKarrels JamesSVP, CFO and Secretary
30,000
0.0481%
$20.50$615,000-82.17%
2024-03-04SaleRisser Eric BlasiusChief Operating Officer
41,159
0.0636%
$19.76$813,501-82.17%
2024-03-04SaleSpitznagel ThomasSr VP, Technical Ops
10,000
0.0156%
$20.00$200,000-82.17%
2024-02-26SalePeters Jeffrey StuartSenior VP and General Counsel
16,124
0.0266%
$17.22$277,655-77.57%
2024-02-07SaleBonvini EzioSr VP, Research & CSO
3,334
0.0069%
$18.00$60,012-76.65%
2024-02-05SalePeters Jeffrey StuartSenior VP and General Counsel
76,251
0.1454%
$16.50$1.26M-75.52%
2024-02-01SaleBonvini EzioSr VP, Research & CSO
13,316
0.0231%
$15.00$199,740-73.02%
2024-01-19SaleBonvini EzioSr VP, Research & CSO
13,316
0.0216%
$12.00$159,792-64.71%
2023-12-20SaleBonvini EzioSr VP, Research & CSO
18,880
0.031%
$10.08$190,310-54.68%
2023-10-02PurchaseBIOTECH TARGET N V10 percent owner
150,000
0.2413%
$4.46$669,585+42.19%
2023-09-07PurchaseBIOTECH TARGET N V10 percent owner
200,000
0.324%
$5.26$1.05M+20.64%
2023-08-30PurchaseHURWITZ EDWARDdirector
15,000
0.0244%
$4.91$73,650+30.00%
2023-03-10SalePeters Jeffrey StuartSenior VP and General Counsel
5,372
0.0099%
$6.03$32,393+19.64%
2023-02-14PurchaseBIOTECH TARGET N V10 percent owner
500,000
0.7819%
$5.07$2.53M+15.84%
2023-01-19PurchaseBIOTECH TARGET N Vdirector
150,000
0.245%
$5.30$794,925+10.10%
2022-12-27PurchaseBIOTECH TARGET N Vdirector
200,000
0.3249%
$5.61$1.12M+1.25%
2022-12-23PurchaseBIOTECH TARGET N Vdirector
200,000
0.3225%
$5.88$1.18M-4.55%
Total: 117
*Gray background shows transactions not older than one year

Insider Historical Profitability

2.15%
BIOTECH TARGET N V10 percent owner
9929963
15.8213%
$22.04M190<0.0001%
Karrels JamesSVP, CFO and Secretary
171452
0.2732%
$380,623.4413+137.87%
Costa Paulo Fdirector
59435
0.0947%
$131,945.7010+41.83%
HURWITZ EDWARDdirector
33074
0.0527%
$73,424.2811+30%
Galbraith Kennethdirector
0
0%
$011<0.0001%

Historical Insider Profitability vs. Competitors

$30,470,407
140
20.39%
$134.78M
$860,541,348
82
-5.10%
$132.49M
$16,245,616
40
123.58%
$122.63M
$909,129
37
42.19%
$127.55M
$64,487,106
32
-22.92%
$140.02M

MGNX Institutional Investors: Active Positions

Increased Positions63+44.68%5M+8.36%
Decreased Positions57-40.43%5M-8.28%
New Positions23New1MNew
Sold Out Positions21Sold Out873,156Sold Out
Total Postitions147+4.26%56M+0.09%

MGNX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Bellevue Group Ag$24,428.0015.76%9.93M00%2024-12-31
Armistice Capital, Llc$15,439.009.96%6.28M+18,000+0.29%2024-12-31
Blackrock, Inc.$12,441.008.03%5.06M-348,297-6.44%2024-12-31
Vanguard Group Inc$10,619.006.85%4.32M-40,859-0.94%2024-12-31
Wasatch Advisors Lp$8,582.005.54%3.49M+952,691+37.57%2024-12-31
Frazier Life Sciences Management, L.P.$7,812.005.04%3.18M+164,938+5.48%2024-12-31
Millennium Management Llc$7,047.004.55%2.86M-671,179-18.98%2024-12-31
State Street Corp$3,598.002.32%1.46M+35,142+2.46%2024-12-31
Geode Capital Management, Llc$3,526.002.28%1.43M+26,341+1.87%2024-12-31
Acadian Asset Management Llc$3,176.002.05%1.29M+199,098+18.23%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
2.6SellsBuysStrong BuyBuyHoldSellStrong SellMGNXHighAverageLowSeries 4